An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT
(Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years
of age) diagnosed with moderate-to-severe primary RLS.